The agency’s sweeping rollout and staff challenge underscore rising momentum behind agentic AI: advanced, multiagent systems ...
GSK and Ideaya first linked up in 2020 to advance novel therapies for solid tumors. It is unclear why the pharma terminated ...
The 2025 meeting of the American Society of Hematology features some of the newest developments in blood cancers and rare ...
Although still in Phase I, Wave Life Sciences’ injectable RNA weight loss treatment achieved results that impressed analysts, ...
Dyne’s exon-skipping therapy zeleciment rostudirsen resulted in an approximately sevenfold increase in dystrophin levels at ...
Analysts at Jefferies see blockbuster potential in zorevunersen in Dravet syndrome, with sales potentially reaching $1 ...
The pharmaceutical supply chain and device development have become intricately linked. Harmonizing formulation development ...
Innovation drives speed in early phase drug development. ICON’s Accelerated Pharmaceutical Solutions integrate advanced ...
As the FDA unveils a parade of initiatives aimed at accelerating drug development for rare diseases, experts appeal for a ...
The R&D pipeline for depression therapies faced a demoralizing 2025 as five high-profile candidates, including KOR ...
Innovative outcome measures coupled with a focus on patient-centered clinical differentiation can help the biopharma industry ...
Tracy Beth Høeg—a known vaccine skeptic—will lead the FDA’s Center for Drug Evaluation and Research as acting chief, becoming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback